Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12101 - 12125 of 12591 in total
Recombinant human lecithin:cholesterol acyltransferase is under investigation in clinical trial NCT03578809 (A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction).
Investigational
Matched Description: … acyltransferase is under investigation in clinical trial NCT03578809 (A Study to Evaluate the Safety and Efficacy of
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
Investigational
Matched Description: … Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ …
Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten …
Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Investigational
Matched Description: … 42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of
Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
Investigational
Matched Description: … Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48 …
SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).
Investigational
Matched Description: … SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered …
V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).
Investigational
Matched Description: … V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 …
Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes).
Investigational
Matched Description: … Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of
Ganaplacide is under investigation in clinical trial NCT03167242 (Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria).
Investigational
Matched Description: … Ganaplacide is under investigation in clinical trial NCT03167242 (Efficacy and Safety of KAF156 in Combination …
Efmitermant alfa, a locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of ACE-083 in Patients With Charcot-marie-tooth Disease).
Investigational
Matched Description: … locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Description: … It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682] …
ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Investigational
Matched Description: … It is under investigation for the treatment of growth hormone deficiency. …
Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).
Investigational
Matched Description: … Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of
Elzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).
Investigational
Matched Description: … Elzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With …
KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.
Investigational
Matched Description: … KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. …
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of
IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III clinical trials.
Investigational
Matched Description: … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. …
AAV-AIPL is an adenovirus-associated viral vector serotype 8 containing the human AIPL1 gene. Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in AIPL1 gene.
Investigational
Matched Description: … Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due …
Vepdegestrant is under investigation in clinical trial NCT05909397 (A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer).
Investigational
Matched Description: … Vepdegestrant is under investigation in clinical trial NCT05909397 (A Study of ARV-471 (PF-07850327) …
Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell...
Investigational
Matched Description: … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor ... affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of ... Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because …
AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency.
Investigational
Matched Description: … After phase II trials it was cancelled due to lack of potency. [L2917] …
Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Investigational
Matched Description: … It is an antigen for the prevention of various major chronic diseases. …
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of
Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to citalopram.
Experimental
Matched Description: … It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. …
USL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)).
Investigational
Matched Description: … USL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in …
Displaying drugs 12101 - 12125 of 12591 in total